Nicotine Dependence

70

Pipeline Programs↗

8

Active Trials↗

38

Companies Involved↗

Nicotine Dependence is a moderately active landscape with 70 programs across 38 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Fertin Pharma A/S, Novo Nordisk. 39 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

65/100

Pipeline Velocity

19/100

Mech. Concentration

8/100

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Fertin Pharma A/S

1 program

Novo Nordisk

2 programs

Glaxo Dba Glaxosmithkline

1 program

COMPASS Pathways

1 program

Axsome Therapeutics, Inc.

1 program

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

73 of 75 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 75 classified programs, each share of the total. Modality classified for 97% of 77 pipeline programs.

Analysis

Trial Status

35

clinical trials

Completed24 · 69%

Recruiting8 · 23%

Terminated2 · 6%

Unknown status1 · 3%

Clinical Trials

Trial Activity

35 trials

Overcoming Nicotine Dependence to Enable Quitting

Recruiting·RRush University Medical Center·Phase 1/2·NCT05513872·780 enrolled

Transcranial Magnetic Stimulation for Nicotine Dependence: An Effectiveness-Implementation Trial

Recruiting·CCentre for Addiction and Mental Health·Phase 4·NCT06534047·40 enrolled

Orexin's Role in The Neurobiology of Substance Use Disorder

Recruiting·National Institute on Drug Abuse (NIDA)·Preclinical·NCT05630781·140 enrolled

Evaluation of Varenicline and Accelerated TMS for Reduction of Nicotine Use

Recruiting·MMassachusetts General Hospital·Approved·NCT07145866·30 enrolled

Cue-Exposure Response Evaluation: Brain Reactivity to ONPs

Recruiting·UUniversity of Southern California·Preclinical·NCT07698470·45 enrolled

The Effect of Flavor and Nicotine Strength on the Abuse Liability and Appeal of Oral Nicotine Products

Recruiting·UUniversity of Southern California·Preclinical·NCT06506162·320 enrolled

An Innovative Digitally-Delivered Olfactory Method for Reducing Cigarette Cravings and Supporting Smoking Cessation

Recruiting·UUniversity of Houston·Phase 1·NCT07007195·132 enrolled

ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT06909500·1,178 enrolled

Treatment of Nicotine Dependence and Acute Depression

Completed·SStanford University·Phase 4·NCT00186446·20 enrolled

Role of Metabolites in Nicotine Dependence (2) - 5

Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00000288

Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence

Completed·MMassachusetts General Hospital·Phase 3·NCT00916721·113 enrolled

An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence

Completed·UUniversity of Pennsylvania·Phase 4·NCT01047527·525 enrolled

Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging

Completed·JJohns Hopkins University·Phase 4·NCT01664741·127 enrolled

Extinction Based Treatment for Nicotine Dependence

Completed·—·Phase 1·NCT00831155·257 enrolled

Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.

Completed·SStanford University·Phase 4·NCT00991081·36 enrolled

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)